Small molecule high throughput screen using AstraZeneca facilities supports academic researchers with assay development and compound screening to identify starting points for small molecule drugs.
Therapeutic Catalyst supports academic researchers in early drug discovery, funding target identification, validation and early antibody or small molecule development to advance treatments for adult cancers.
Childhood Cancer Therapeutic Catalyst supports academic researchers in collaborative early drug discovery to advance novel therapeutics for children and young people with cancer.
Cancer Research UK's CDD supports the development of novel cancer agents from preclinical stages to early clinical trials with expert resources, not monetary funding.
UKRI Translation: MRC Proof of Concept: stage one supports academic teams developing and testing medical interventions and research tools to address significant health needs and advance patient benefit.
Isambard-AI and Zenith AIRR supercomputers: Rapid Access route supports UK small and medium-sized businesses with computing resources to research and develop early-stage AI products before market launch.